Valink Therapeutics
ActiveDiscovering bispecific antibody drug-conjugates (BsADC) against cancer
This company has previously operated under “SpyCombinator”, “LiliumX”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Founders · 2
Rhodes Scholar & DPhil Biochemistry from the University of Oxford
Pharma analyst with a background in protein engineering DPhil in Biochemistry from the University of Oxford
Related startups
Multi-targeted therapeutics to treat complex diseases
We use AI to design antibodies for intractable diseases
